{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:54:42Z","timestamp":1771062882838,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Intravitreale operative Medikamenteneingaben (IVOM) stellen einen der h\u00e4ufigsten Eingriffe in der Medizin dar. Das Risikoprofil ist gering. Neben intraokularen Drucksteigerungen z\u00e4hlen insbesondere erregerbedingte Endophthalmitiden, Glask\u00f6rperblutungen und rhegmatogene Netzhautabl\u00f6sungen zu den g\u00e4ngigen Komplikationen. Dar\u00fcber hinaus wurden auch einzelne F\u00e4lle von Linsenverletzungen sowie peripheren Netzhautdefekten und Makulaforamina in Assoziation mit vitreoretinalen Traktionen beschrieben. In der hier vorliegenden Fallserie berichten wir \u00fcber scharfe iatrogene Netzhaut- bzw. Makulaverletzungen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Multizentrische Fallsammlung von IVOM-Patienten mit iatrogenen Netzhautdefekten, retrospektiv \u00fcber den Zeitraum 2016 bis 2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es konnten 9\u00a0F\u00e4lle (72\u00a0Jahre\u202f\u00b1\u20098,1, 3\u00a0Augen pseudophak) mit einem iatrogenen retinalen Trauma nach IVOM zur Therapie einer neovaskul\u00e4ren altersbedingten Makuladegeneration (nAMD) dokumentiert werden. W\u00e4hrend in 6\u00a0F\u00e4llen scharfe Verletzungen innerhalb der Makula vorlagen, waren die L\u00e4sionen in den anderen F\u00e4llen extramakul\u00e4r lokalisiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Iatrogene Netzhaut- und Makulaverletzungen sind seltene Komplikationen im Rahmen der IVOM und bei sachgem\u00e4\u00dfer Durchf\u00fchrung insbesondere mit Blick auf die Kan\u00fclenverwendung und die Wahl des Limbusabstands vermeidbar.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-023-01976-5","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T08:02:45Z","timestamp":1705046565000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iatrogene Netzhautdefekte nach intravitrealer operativer Medikamenteneingabe","Iatrogenic retinal defects after intravitreal operative drug injections"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-1680","authenticated-orcid":false,"given":"David A.","family":"M\u00e4rker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Radeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Alten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph R.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"1976_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00347-021-01454-w","volume":"119","author":"C Wolfram","year":"2022","unstructured":"Wolfram\u00a0C, Schargus\u00a0M (2022) Das Hamburger Register f\u00fcr intravitreale Injektionstherapien (QIVOM). Ophthalmologe 119:280\u2013287. https:\/\/doi.org\/10.1007\/s00347-021-01454-w","journal-title":"Ophthalmologe"},{"key":"1976_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00347-021-01553-8","volume":"119","author":"C Framme","year":"2022","unstructured":"Framme\u00a0C, Junker\u00a0B, Feltgen\u00a0N et\u00a0al (2022) Indikationen zur intravitrealen Injektionstherapie mit Anti-VEGF f\u00fcr Makulaerkrankungen \u2013 Fehler vermeiden. Ophthalmologe 119:309\u2013326. https:\/\/doi.org\/10.1007\/s00347-021-01553-8","journal-title":"Ophthalmologe"},{"key":"1976_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani\u00a0KG, Nguyen\u00a0QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a\u00a0review of literature. Nature 27:787\u2013794. https:\/\/doi.org\/10.1038\/eye.2013.107","journal-title":"Nature"},{"key":"1976_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1089\/jop.2010.0045","volume":"26","author":"CH Meyer","year":"2010","unstructured":"Meyer\u00a0CH, Rodrigues\u00a0EB, Michels\u00a0S et\u00a0al (2010) Incidence of damage to the crystalline lens during intravitreal injections. J\u00a0Ocul Pharmacol Ther 26:491\u2013495. https:\/\/doi.org\/10.1089\/jop.2010.0045","journal-title":"J Ocul Pharmacol Ther"},{"key":"1976_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/cxo.12009","volume":"97","author":"HA Tufan","year":"2013","unstructured":"Tufan\u00a0HA, Gencer\u00a0B, Kara\u00a0S (2013) Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation. Clin Exp Optom 97:178\u2013180. https:\/\/doi.org\/10.1111\/cxo.12009","journal-title":"Clin Exp Optom"},{"key":"1976_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1324-4","author":"D Muramatsu","year":"2015","unstructured":"Muramatsu\u00a0D, Mitsuhashi\u00a0R, Iwasaki\u00a0T et\u00a0al (2015) Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a\u00a0case report. BMC Res Notes. https:\/\/doi.org\/10.1186\/s13104-015-1324-4","journal-title":"BMC Res Notes"},{"key":"1976_CR7","doi-asserted-by":"publisher","first-page":"1706234","DOI":"10.1155\/2016\/1706234","volume":"2016","author":"L Christensen","year":"2016","unstructured":"Christensen\u00a0L, Sanders\u00a0R, Olson\u00a0J (2016) \u201cMagic bullet\u201d: eccentric macular hole as a complication from Dexamethasone implant insertion. Case Rep Ophthalmol Med 2016:1706234. https:\/\/doi.org\/10.1155\/2016\/1706234","journal-title":"Case Rep Ophthalmol Med"},{"key":"1976_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4274\/tjo.galenos.2019.98975","volume":"49","author":"C Ekinci","year":"2019","unstructured":"Ekinci\u00a0C, Kay\u0131ran\u00a0A, \u00d6zdemir\u00a0H (2019) Extramacular retinal hole following intravitreal Dexamethasone implant: case report. tjo 49:175\u2013177. https:\/\/doi.org\/10.4274\/tjo.galenos.2019.98975","journal-title":"tjo"},{"key":"1976_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ophtha.2020.11.014","volume":"128","author":"SK Propst","year":"2020","unstructured":"Propst\u00a0SK, Seider\u00a0MI, Vora\u00a0RA (2020) Jet stream maculopathy. Ophthalmology 128:718. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.014","journal-title":"Ophthalmology"},{"key":"1976_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000512695","volume":"12","author":"K Kishore","year":"2021","unstructured":"Kishore\u00a0K, McGowan\u00a0DS, Hanebrink\u00a0KA (2021) Iatrogenic retinal penetration from Intravitreal injections. Case Rep Ophthalmol 12:248\u2013253. https:\/\/doi.org\/10.1159\/000512695","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"1976_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2011.09.002","volume":"119","author":"A Sudhalkar","year":"2012","unstructured":"Sudhalkar\u00a0A, Chauhan\u00a0P, Sudhalkar\u00a0A, Trivedi\u00a0RH (2012) Pars plana width and sclerotomy sites. Ophthalmology 119(1):198\u2013199.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2011.09.002","journal-title":"Ophthalmology"},{"issue":"6","key":"1976_CR12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00417-020-04967-3","volume":"259","author":"J-B Lincke","year":"2021","unstructured":"Lincke\u00a0J\u2011B, Keller\u00a0S, Amaral\u00a0J, Zinkernagel\u00a0MS, Schuerch\u00a0K (2021) Ciliary body length revisited by anterior segment optical coherence tomography: implications for safe access to the pars plana for intravitreal injections. Graefes Arch Clin Exp Ophthalmol 259(6):1435\u20131441. https:\/\/doi.org\/10.1007\/s00417-020-04967-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1976_CR13","unstructured":"https:\/\/www.dog.org\/wp-content\/uploads\/2009\/09\/DOG_Empfehlung_Intravitreale_Injektionen.pdf"},{"issue":"4","key":"1976_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski\u00a0A, Told\u00a0R, Sacu\u00a0S, Bandello\u00a0F, Moisseiev\u00a0E, Loewenstein\u00a0A, Schmidt-Erfurth\u00a0U (2018) Euretina board; 2018 update on intravitreal injections: euretina expert consensus. Recomm Ophthalmol 239(4):181\u2013193. https:\/\/doi.org\/10.1159\/000486145","journal-title":"Recomm Ophthalmol"},{"issue":"3","key":"1976_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3233\/THC-160777","volume":"26","author":"A Karimi","year":"2018","unstructured":"Karimi\u00a0A, Razaghi\u00a0R, Biglari\u00a0H, Sabbaghi\u00a0H, Sera\u00a0T, Kudo\u00a0S (2018) A\u00a0comparative study to determine the optimal intravitreal injection angle to the eye: A\u00a0computational fluid-structure interaction model. Technol Health Care 26(3):483\u2013498. https:\/\/doi.org\/10.3233\/THC-160777","journal-title":"Technol Health Care"},{"issue":"1","key":"1976_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/IAE.0b013e3181b094cf","volume":"30","author":"J-P Hubschman","year":"2010","unstructured":"Hubschman\u00a0J\u2011P, Coffee\u00a0RE, Bourges\u00a0J\u2011L, Yu\u00a0F, Schwartz\u00a0SD (2010) Experimental model of intravitreal injection techniques. Retina 30(1):167\u2013173. https:\/\/doi.org\/10.1097\/IAE.0b013e3181b094cf","journal-title":"Retina"},{"key":"1976_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3238\/arztebl.m2022.0222","volume":"119","author":"D Dr\u00fcke","year":"2022","unstructured":"Dr\u00fcke\u00a0D, Feltgen\u00a0N, Hoerauf\u00a0H (2022) Loss of visual acuity following acupuncture. Dtsch \u00c4rztebl Int 119:663. https:\/\/doi.org\/10.3238\/arztebl.m2022.0222","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"1976_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0896-1549(05)70257-1","volume":"14","author":"H Rodriguez-Coleman","year":"2001","unstructured":"Rodriguez-Coleman\u00a0H, Spaide\u00a0R (2001) Ocular complications of needle perforations during retrobulbar and peribulbar injections. Ophthalmol Clin North Am 14:573\u2013579. https:\/\/doi.org\/10.1016\/s0896-1549(05)70257-1","journal-title":"Ophthalmol Clin North Am"},{"key":"1976_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/bjo.66.10.625","volume":"66","author":"P Brown","year":"1982","unstructured":"Brown\u00a0P, Chignell\u00a0AH (1982) Accidental drainage of subretinal fluid. Br J Ophthalmol 66:625. https:\/\/doi.org\/10.1136\/bjo.66.10.625","journal-title":"Br J Ophthalmol"},{"key":"1976_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaapos.2004.03.003","volume":"8","author":"Y Dang","year":"2004","unstructured":"Dang\u00a0Y, Racu\u00a0C, Isenberg\u00a0SJ (2004) Scleral penetrations and perforations in strabismus surgery and associated risk factors. J\u00a0Am Assoc Pediatr Ophthalmol Strabismus 8:325\u2013331. https:\/\/doi.org\/10.1016\/j.jaapos.2004.03.003","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"1976_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0002-9394(03)00837-7","volume":"137","author":"M Liu","year":"2004","unstructured":"Liu\u00a0M, Lee\u00a0HC, Hertle\u00a0RW, Ho\u00a0AC (2004) Retinal detachment from inadvertent intraocular injection of botulinum toxin A. Am J Ophthalmol 137:201\u2013202. https:\/\/doi.org\/10.1016\/s0002-9394(03)00837-7","journal-title":"Am J Ophthalmol"},{"key":"1976_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2474126419868888","volume":"4","author":"RC Bowen","year":"2020","unstructured":"Bowen\u00a0RC, Possin\u00a0ME, Altaweel\u00a0MM (2020) Bilateral globe penetration from electromyography electrode placement for intraoperative neurophysiologic monitoring. J\u00a0Vitr Dis 4:136\u2013138. https:\/\/doi.org\/10.1177\/2474126419868888","journal-title":"J Vitr Dis"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-023-01976-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T11:15:12Z","timestamp":1707390912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-023-01976-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1007\/s00347-023-01976-5","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.A. M\u00e4rker: Honorar: Bayer, Novartis; Advisory Board: Novartis, Alcon. H.\u00a0Helbig: Honorar: Alcon, Novartis, Roche, AbbVie; Support for meetings\/travel: Bayer; Advisory Board: Alcon, Novartis, Roche, Bayer, Aspellis AbbVie, Theapharm; Leadership: RG Vorstand, DOG Pressesprecher. N.\u00a0Eter: Honorar: Allergan, Aspellis, Bayer, Novartis, Roche, Stada, AbbVie; Advisory Board: Apellis, Bayer, Novartis, Roche, Biogen, Janssen. F.\u00a0Alten: Honorar: Bayer; C.R.\u00a0Clemens: Honorar: Bayer, Novartis, Heidelberg Engineering. V.\u00a0Radeck, F.\u00a0Lehmann und T.\u00a0Barth geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}